Explore the key medtech trends to watch in 2026, from China's procurement reforms and ASC migration to supply chain resilience, GLP-1 therapies, and platform-based competition.

An analysis of Deloitte's Tech Trends 2026 and its strategic implications for international business, investment, and governance.

An analysis of the 2026 Wasabi Global Cloud Storage Index and its implications for international business, digital infrastructure investment, and data sovereignty policies.

An analysis of five medtech trends for 2026—China pricing reforms, outpatient migration, supply chain resilience, GLP-1 impact, and platform innovation—and their strategic implications for global healthcare, business, and policy.

Explore the 16 business trends set to define 2026, from AI and e-commerce to sustainability and skills-based hiring, with a focus on their global economic impact.

An in-depth analysis of how China's evolving industrial strategy is becoming more systemic, accelerating trade dominance, and reshaping global supply chains.

An evidence-based analysis of the business trends set to shape the global economy in 2026, with strategic insights for policymakers, investors, and multinational executives.

An analysis of five key medtech trends in 2026, from China's volume-based procurement to GLP-1 therapies and platform-based competition, and their international economic and strategic consequences.

An analysis of five structural forces transforming the medtech industry: China's VBP expansion, outpatient migration, supply chain reconfiguration, GLP-1 drug impact, and platform-based competition.

An analysis of five key medtech trends driving structural change in global healthcare markets, from China's volume-based procurement to platform competition.

A new report from Boston Consulting Group and HealthKois reveals that while India’s life sciences sector has achieved notable milestones in innovation, structural gaps in funding, clinical execution, and supply chains hinder its ability to scale. The findings carry significant implications for global pharmaceutical supply chains, investment flows, and the future of affordable therapeutics.